Related Experiment Video
Updated: Jul 16, 2026
11:15
Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
Dendritic cell-based active specific immunotherapy for malignant glioma
Prahlad Parajuli1, Saroj Mathupala, Sandeep Mittal
1Wayne State University and Karmanos Cancer Institute, Department of Neurosurgery, Hudson-Webber CRC #808, 4100 John R St, Detroit, MI-48201, USA. pparajuli@med.wayne.edu
Expert Opinion on Biological Therapy
|March 22, 2007
Summary
Dendritic cell immunotherapy shows promise for malignant gliomas by targeting residual cancer cells. Future strategies focus on overcoming immune suppression for more effective treatment.
Area of Science:
- Neuro-oncology
- Immunology
- Cancer Therapy
Background:
- Malignant gliomas are challenging to treat due to invasive tumor cells.
- Dendritic cell (DC)-based immunotherapy aims to induce cell-mediated immunity and memory responses against residual glioma cells.
- Early clinical trials showed limited success, necessitating further research.
Purpose of the Study:
- To review the evolution of DC-based immunotherapy strategies for malignant gliomas.
- To discuss novel approaches for enhancing DC maturation and activation.
- To explore how understanding tumor-induced immune suppression influences future glioma immunotherapy.
Main Methods:
- Review of existing literature on dendritic cell immunotherapy for malignant gliomas.
- Analysis of studies investigating novel adjuvants for DC maturation.
- Examination of research on tumor immune evasion mechanisms, including regulatory T cells.
Main Results:
- Initial DC immunotherapy trials for gliomas yielded limited clinical benefits.
- Development of new strategies using novel adjuvants to improve DC maturation and activation.
- Increased focus on understanding tumor-intrinsic immune suppression and regulatory T cell roles.
Conclusions:
- DC-based immunotherapy remains a promising avenue for adjuvant treatment of malignant gliomas.
- Overcoming tumor-induced immune suppression is critical for enhancing therapeutic efficacy.
- Future immunotherapy for high-grade gliomas will likely integrate insights into tumor tolerance mechanisms.
Related Concept Videos
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:30Cancer Vaccines
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...